At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed persistent and/or locoregionally recurrent HNSCC
- ✓Oral cavity, pharynx, larynx, or unknown primary squamous cell carcinoma
- ✓Resectable disease as determined by surgeon and team
- ✓At least 18 years of age
- ✕Salivary gland carcinomas, lip carcinoma, adenocarcinoma of skin
- ✕Prior use of immune checkpoint blockade agent
- ✕History of HIV, hepatitis B or C
- ✕Unresectable disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HNSALV Trial: Combining Immunotherapy With Salvage Surgery and IORT for Treatment of Persistent/Recurrent Head and Neck Cancers
In Brief
A Phase 1 clinical trial evaluating External Beam Radiation Therapy, Intraoperative Radiation Therapy, and 3 other interventions for Head and Neck Carcinoma of Unknown Primary and 5 related conditions. Currently recruiting, targeting 45 participants across 1 site.
Detailed Summary
This phase I trial is to find out the possible side effects of pembrolizumab and radiation therapy before and during surgery in treating patients with head and neck squamous cell cancer that remains despite treatment (persistent) or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays or protons to kill tumor cells and shrink tumors. Giving pembrolizumab and radiation therapy before and during surgery may kill more tumor cells.
Study Details
Timeline
Interventions
Undergo EBRT
Undergo IORT
Given IV
Ancillary studies
Undergo salvage surgery